Literature DB >> 24742844

Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival.

Junna Oba1, Takeshi Nakahara2, Takeru Abe3, Akihito Hagihara4, Yoichi Moroi1, Masutaka Furue1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24742844     DOI： 10.1016/j.jaad.2014.01.880

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  12 in total

1.  Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.

Authors:  Fuyou Zhao; Qiong Wu; Xiusong Dai; Yumei Li; Huaiyong Gan; Ri Wang; Jie Lv; Yuqing Chen
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

Review 2.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

3.  Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.

Authors:  Annikka Weissferdt; Junya Fujimoto; Neda Kalhor; Jaime Rodriguez; Roland Bassett; Ignacio I Wistuba; Cesar A Moran
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

Review 4.  Immune checkpoint inhibitors in clinical trials.

Authors:  Elad Sharon; Howard Streicher; Priscila Goncalves; Helen X Chen
Journal:  Chin J Cancer       Date:  2014-09

Review 5.  Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

Authors:  Florencia Paula Madorsky Rowdo; Antonela Baron; Mariela Urrutia; José Mordoh
Journal:  Front Immunol       Date:  2015-03-26       Impact factor: 7.561

6.  Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.

Authors:  Tianqi Xu; Jia Chai; Kaijing Wang; Qingge Jia; Yixiong Liu; Yingmei Wang; Junpeng Xu; Kangjie Yu; Danhui Zhao; Jing Ma; Linni Fan; Qingguo Yan; Shuangping Guo; Gang Chen; Qiongrong Chen; Hualiang Xiao; Fang Liu; Chubo Qi; Rong Liang; Mingyang Li; Zhe Wang
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

7.  Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.

Authors:  Giosuè Scognamiglio; Anna De Chiara; Maurizio Di Bonito; Fabiana Tatangelo; Nunzia Simona Losito; Annamaria Anniciello; Rossella De Cecio; Crescenzo D'Alterio; Stefania Scala; Monica Cantile; Gerardo Botti
Journal:  Int J Mol Sci       Date:  2016-05-21       Impact factor: 5.923

8.  Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.

Authors:  Jing Zeng; Xin-Ke Zhang; Hua-Dong Chen; Zhi-Hai Zhong; Qiu-Liang Wu; Su-Xia Lin
Journal:  Oncotarget       Date:  2016-02-23

9.  Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.

Authors:  Ling Dong; Huijuan Lv; Wei Li; Zheng Song; Lanfang Li; Shiyong Zhou; Lihua Qiu; Zhengzi Qian; Xianming Liu; Lixia Feng; Bin Meng; Kai Fu; Xi Wang; Qiang Pan-Hammarström; Ping Wang; Xianhuo Wang; Huilai Zhang
Journal:  Oncotarget       Date:  2016-05-31

10.  CD10-Equipped Melanoma Cells Acquire Highly Potent Tumorigenic Activity: A Plausible Explanation of Their Significance for a Poor Prognosis.

Authors:  Junna Oba; Takeshi Nakahara; Akiko Hashimoto-Hachiya; Min Liu; Takeru Abe; Akihito Hagihara; Takehiko Yokomizo; Masutaka Furue
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.